浙江康恩贝制药股份有限公司关于2022年股票期权激励计划部分股票期权注销完成的公告

Core Points - The company announced the completion of the cancellation of certain stock options from the 2022 stock option incentive plan due to the disqualification of some participants [2] - A total of 2.0292 million stock options were canceled, which will not affect the company's share capital [2] Group 1: Stock Option Cancellation - The board of directors and the supervisory board approved the cancellation of stock options for individuals who no longer meet the eligibility criteria due to retirement or resignation [2] - The cancellation was confirmed by the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, and completed on November 12, 2025 [2] Group 2: Shareholder Meeting - The company held its first temporary shareholder meeting on November 13, 2025, with no resolutions being rejected [5] - The meeting was conducted in accordance with the Company Law and the company's articles of association, combining on-site and online voting [6] - Key resolutions included amendments to the company's articles of association and governance rules, all of which were passed with significant support from shareholders [8]